SIU 2017: Comparison of Multiparametric and Biparametric MRI Cognitive Targeted First Round Prostate Biopsy for Patients with a PSA Level under 10 Ng/Ml

Lisbon, Portugal (UroToday.com) This study attempted to determine the efficacy of cognitive targeted prostate biopsy using bi-parametric magnetic resonance imaging (b-MRI) for patients with a PSA level less than 10 ng/ml.

The authors reviewed data from 154 consecutive male patients who underwent cognitive targeted prostate biopsy using prostate MRI in 2016. Of these patients, the first 66 underwent prostate biopsy using multi parametric MRI (mp-MRI), and he remaining 88 underwent prostate biopsy using b-MRI. For b-MRI, the authors only performed T2 weighted axial imaging and diffusion-weighted imaging sequences. 79 of the 154 men had suspicious lesions on MRI (38 of the 66 men in the mpMRI group and 41 of the 88 men in the b-MRI group).  The authors then compared the prostate cancer detection rates and the proportions of clinically significant prostate cancer between the different MRI sequences.

Between the two MRI groups, the PSA levels were very similar and there were no statistically significant differences in prostate cancer detection rate or proportion of clinically significant prostate cancer (41.8% vs. 30.9%, p=0.208 and 82.6% vs. 76.2%, p=0.598). Among the 79 men who had suspicious lesions on MRI, the prostate cancer detection rates were 63.2% and 62.8% (p=0.973) in the mp-MRI and b-MRI groups, respectively, and the proportions of clinically significant prostate cancer were 91.8% and 81.5% (p=0.291).

It was the conclusion of the authors that prostate biopsy using b-MRI showed similar performance to that of using mp-MRI, in regards to prostate cancer detection and specifically for clinically significant prostate cancer in patients with a PSA level less than 10 ng/ml. Considering the satisfactory performance and cost effectiveness of b-MRI, this technique could be a good option for obtaining prostatic information for first round prostate biopsy.


Presented by: Lee DH
Affiliation: Pusan National University Yangsan Hospital, Seoul, South Korea

Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre.Twitter: @GoldbergHanan at the 37th Congress of Société Internationale d’Urologie - October 19-22, 2017- Lisbon, Portugal
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe